Publications by authors named "Jean-Baptiste Rieu"
According to current recommendations, older AML patients in first complete remission (CR) after induction chemotherapy should receive consolidation with intermediate-dose cytarabine (IDAC). However, no study has demonstrated the superiority of IDAC over other regimen. In this retrospective study, we compared the efficacy of mini-consolidations (idarubicin 8 mg/m day 1, cytarabine 50 mg/m/12 h, day 1-5) and IDAC.
View Article and Find Full Text PDF[Quand la leucémie à tricholeucocytes rencontre la légionellose].
Ann Biol Clin (Paris)
September 2024
Article Synopsis
- Acute myeloid leukemia (AML) with BCR::ABL1 is classified as an adverse-risk group in the 2022 ELN classification, but its outcomes with modern treatment options like tyrosine kinase inhibitors are not well understood.
- In a study of 20 patients with de novo BCR::ABL1 AML from a large registry, most received standard chemotherapy with imatinib, leading to a high complete remission rate of 94.4%.
- The survival rates suggest BCR::ABL1 AML patients have better outcomes than those classified in traditional adverse-risk categories, indicating they may need reclassification in future treatment guidelines.
Article Synopsis
- Acute myeloid leukemia (AML) with myelodysplasia-related characteristics presents a mixed prognosis, and there's limited understanding of patient outcomes after first-line treatment in refractory or relapsed cases.
- A study involving 183 patients found that the median overall survival was 4.2 months, with no significant survival difference between refractory and relapsed patients; however, patients receiving best supportive care had markedly poorer outcomes.
- The research suggests that both intensive chemotherapy and azacitidine are viable treatment options for this tough-to-treat population, and emphasizes the need for further exploration of new targeted therapies.
Article Synopsis
- Researchers created AI-based prediction models using data from 3,687 acute myeloid leukemia patients, focusing on two treatment types: intensive chemotherapy and azacitidine.
- A multilayer perceptron neural network demonstrated prediction accuracies of 68.5% for intensive chemotherapy patients and 62.1% for those treated with azacitidine.
- The Boruta algorithm effectively identified key diagnostic features needed for predictions, streamlining the complexity of data analysis for hematologists and potentially improving treatment decisions.
Article Synopsis
- Recent research indicates that vitamins C and D may play a role in supporting patients with acute myeloid leukemia (AML) during intensive chemotherapy.!
- A study tracking 431 AML patients from 2015 to 2020 found that those who received vitamin supplementation showed higher vitamin levels and fewer complications like infections compared to those who didn’t.!
- The analysis revealed that vitamin C/D supplementation significantly improved overall survival for patients with the NPM1 mutation, suggesting it could be a beneficial addition to AML treatment protocols.!
Use of a hybrid intelligence decision tree to identify mature B-cell neoplasms.
Cytometry B Clin Cytom
August 2023
Article Synopsis
- Mature B-cell neoplasms are difficult to diagnose because they have varied features and can resemble each other, which complicates the process.
- The study introduces a new method that combines flow cytometry data with AI to create a decision tree for identifying these neoplasms, specifically targeting chronic lymphocytic leukemia (CLL) among other types.
- The developed decision tree simplifies diagnosis, requiring only three markers (CD5, CD43, and CD200) to effectively identify most CLL cases, potentially enhancing diagnostic accuracy and efficiency.
Article Synopsis
- Acute myeloid leukemia (AML) is linked to leukemic stem cells (LSC), which affect patient responses to chemotherapy and overall survival, highlighting the importance of measuring LSC levels.
- A study evaluated 155 AML patients post-chemotherapy to assess the effectiveness of detecting measurable residual disease (MRD) in both bulk and LSC populations, using unsupervised clustering methods.
- Results showed a significant difference in overall survival rates between patients with positive MRD and those who tested negative, with some patients having negative Bulk MRD but positive LSC MRD, indicating these individuals have an intermediate prognosis.
Article Synopsis
- Researchers have developed a new classification system for acute myeloid leukemia (AML) using flow cytometry to identify six stages of differentiation arrest in leukemic cells based on specific protein expressions.
- The study analyzed two patient cohorts and found that different types of AML (stem cell-like versus progenitor-like) display distinct genetic characteristics, proliferation rates, and treatment responses, which influence patient outcomes.
- Factors such as NPM1 mutations are associated with more mature leukemia stages, while other genetic mutations (like CEBPA and RUNX1) help predict the severity and treatment efficacy for AML patients.
In order to standardize cellular hematology practices, the French-speaking Cellular Hematology Group (Groupe Francophone d'Hématologie Cellulaire, GFHC) focused on Perls' stain. A national survey was carried out, leading to the proposal of recommendations on insoluble iron detection and quantification in bone marrow. The criteria presented here met with a "strong professional agreement" and follow the suggestions of the World Health Organization's classification of hematological malignancies.
View Article and Find Full Text PDF